#### Check for updates

#### OPEN ACCESS

EDITED BY John Mitrofanis, Université Grenoble Alpes, France

#### REVIEWED BY

Lew Lim, Vielight Inc., Canada Dan Johnstone, The University of Newcastle, Australia Ann Liebert, Sydney Adventist Hospital, Australia

\*CORRESPONDENCE Fabrízio dos Santos Cardoso fabriziooscardoso@yahoo.com.br

#### SPECIALTY SECTION

This article was submitted to Neuroenergetics, Nutrition and Brain Health, a section of the journal Frontiers in Neuroscience

RECEIVED 28 July 2022 ACCEPTED 31 August 2022 PUBLISHED 20 September 2022

#### CITATION

Cardoso FdS, Salehpour F, Coimbra NC, Gonzalez-Lima F and Gomes da Silva S (2022) Photobiomodulation for the treatment of neuroinflammation: A systematic review of controlled laboratory animal studies. *Front. Neurosci.* 16:1006031. doi: 10.3389/fnins.2022.1006031

#### COPYRIGHT

© 2022 Cardoso, Salehpour, Coimbra, Gonzalez-Lima and Gomes da Silva. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Photobiomodulation for the treatment of neuroinflammation: A systematic review of controlled laboratory animal studies

Fabrízio dos Santos Cardoso<sup>1\*</sup>, Farzad Salehpour<sup>2</sup>, Norberto Cysne Coimbra<sup>1</sup>, Francisco Gonzalez-Lima<sup>2</sup> and Sérgio Gomes da Silva<sup>3,4</sup>

<sup>1</sup>Departamento de Farmacologia, Faculdade de Medicina de Ribeirão da Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil, <sup>2</sup>Department of Psychology and Institute for Neuroscience, University of Texas at Austin, Austin, TX, United States, <sup>3</sup>Centro Universitário UNIFAMINAS (UNIFAMINAS), Muriaé, MG, Brazil, <sup>4</sup>Hospital do Câncer de Muriaé, Fundação Cristiano Varella (FCV), Muriaé, MG, Brazil

**Background:** Neuroinflammation is a response that involves different cell lineages of the central nervous system, such as neurons and glial cells. Among the non-pharmacological interventions for neuroinflammation, photobiomodulation (PBM) is gaining prominence because of its beneficial effects found in experimental brain research. We systematically reviewed the effects of PBM on laboratory animal models, specially to investigate potential benefits of PBM as an efficient anti-inflammatory therapy.

**Methods:** We conducted a systematic search on the bibliographic databases (PubMed and ScienceDirect) with the keywords based on MeSH terms: photobiomodulation, low-level laser therapy, brain, neuroinflammation, inflammation, cytokine, and microglia. Data search was limited from 2009 to June 2022. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. The initial systematic search identified 140 articles. Among them, 54 articles were removed for duplication and 59 articles by screening. Therefore, 27 studies met the inclusion criteria.

**Results:** The studies showed that PBM has anti-inflammatory properties in several conditions, such as traumatic brain injury, edema formation and hyperalgesia, ischemia, neurodegenerative conditions, aging, epilepsy, depression, and spinal cord injury.

**Conclusion:** Taken together, these results indicate that transcranial PBM therapy is a promising strategy to treat brain pathological conditions induced by neuroinflammation.

#### KEYWORDS

photobiomodulation, low-level laser (light) therapy, brain, neuroinflammation, inflammation, cytokine, microglia

# Introduction

Neuroinflammation is a response that involves cells of the central nervous system (CNS) such as neurons, macroglia and microglia (DiSabato et al., 2016; Schain and Kreisl, 2017; Shabab et al., 2017). This response is mainly mediated by cytokines, chemokines, secondary messengers, and reactive oxygen species (ROS) (Glass et al., 2010; Park et al., 2011; DiSabato et al., 2016; Norden et al., 2016). Neuroinflammation also can be a pathological condition in a variety of neurodegenerative diseases ((Schain and Kreisl, 2017)). For example, the activation of microglia, pro-inflammatory cytokines and signaling pathways linked to inflammation such as nuclear factor kappa-lightchain-enhancer of activated B cells (NF-KB) pathway can trigger neurodegeneration (Glass et al., 2010; Harry and Kraft, 2012; Lyman et al., 2014). The prolonged release of pro-inflammatory mediators such as tumor necrosis factoralpha (TNF- $\alpha$ ), interleukin (IL)-1 $\alpha$ , IL-1 $\beta$ , and IL-6 allow leukocytes to migrate into the brain and induce pathogenesis in the CNS (De Vries et al., 1996; Laflamme et al., 1999). In addition, this inflammatory reaction leads to synaptic gene dysregulation, tissue damage, and potentially cell death (Cunningham et al., 1996; Carson et al., 2006; DiSabato et al., 2016). Given this scenario, new therapeutic approaches are needed to modulate neuroinflammatory responses in pathological conditions.

Photobiomodulation (PBM), or low-level laser/light therapy (LLLT) (Anders et al., 2015), is a non-invasive light-driven intervention that involves the use of red and near-infrared (NIR) light to stimulate healing processes, reduce pain, protect the aging brain and decrease inflammation in several tissues, including the nervous tissue (Rojas and Gonzalez-Lima, 2011, 2013; Almeida et al., 2013; Arany, 2016; Hamblin, 2017; Cardoso et al., 2021a,b). These effects may be mediated by multiple mechanisms. However, cytochrome c oxidase (CCO), the fourth enzyme complex in the electron transport chain within mitochondria, is the main photoacceptor when cells are irradiated with the red to NIR light used for PBM (Karu, 1999). Cellular studies have also shown that PBM promotes ATP synthesis in mitochondria (Karu et al., 1995), and release of mitochondrial ROS and nitric oxide (Karu et al., 2005; Huang et al., 2009). These upstream processes contribute to increased cellular metabolism, altered mitochondrial dynamics, increased vasodilation, and mainly decreased inflammation (Pastore et al., 1994; Karu et al., 2005; Muili et al., 2012; Plass et al., 2012). In the brain in vivo, a primary PBM mechanism has been confirmed to be photonic oxidation of mitochondrial CCO (Wang et al., 2017a; Saucedo et al., 2021), being this mechanism independent of heat/thermal effects induced by light (Wang et al., 2017b). Brain PBM leads secondarily to increased cerebrovascular oxygenation (Tian et al., 2016; Holmes et al., 2019), the activation of metabolic pathways (Cardoso et al., 2021c), and of intracellular signaling molecules (Cardoso et al., 2021d), some of them relevant for inflammation

(Cardoso et al., 2021a). The mitochondrial mechanism of PBM may provide a link between PBM and inflammation considering that recent studies have uncovered mitochondrial molecules, called mitochondrial alarmins, with inflammatory signaling properties (Grazioli and Pugin, 2018).

In favor of idea, it has been noted that PBM can alter the levels of inflammatory mediators in various animal models (Gupta et al., 2015; Martins et al., 2016; Yoshimura et al., 2016). For example, Gupta et al. (2015) demonstrated that 904 nm laser PBM enhances the healing of burn wounds in rats and attenuates inflammation by decreasing the expression of TNF- $\alpha$ and NF-kB, and by up-regulated expression of VEGF, FGFR-1, HSP-60, and HIF-1 $\alpha$  at 4- and 7-days post-wounding. Martins et al. (2016) administered 950 nm laser PBM therapy in an animal model of inflammatory pain and found that the animals exhibited a reduced pain and an improvement of antioxidant enzymes and high levels of the anti-inflammatory cytokine IL-10. In a mouse model of obesity and type 2 diabetes mellitus, six sessions of 830 nm laser PBM were also able to reduce abdominal adipose tissue inflammation (Yoshimura et al., 2016).

In recent years, promising evidence has emerged to support the anti-inflammatory effects of the PBM therapy in various animal models in different neurological conditions (Khuman et al., 2012; Hamblin, 2017; Salehpour et al., 2019a,b; Cho et al., 2020; Cardoso et al., 2021a; Yang et al., 2021a). In this systematic review, we analyzed the neuroinflammatory effects of PBM on animal models of brain pathological conditions, in special to investigate potential translational benefits of PBM as an anti-inflammatory transcranial therapy.

# Materials and methods

## Data sources and search strategy

The search was conducted from 2009 to June 2022. PubMed and ScienceDirect were searched electronically with the keywords "photobiomodulation" or "low-level laser therapy" or "LLLT"; and "brain"; and "inflammation" or "cytokine" or "microglia" or "neuroinflammation" (Table 1). To ensure the clarity and transparency of the articles, we used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2010). Two independent researchers screened the title, abstract, and the full text of the articles and judged the searched materials against the inclusion and exclusion criteria. Disagreements were resolved by consensus.

# Selection criteria

We selected all *in vivo* studies to obtain findings related to neuroinflammatory effect of PBM in brain disorders

TABLE 1	Summary of laboratory animal studies on
neuroinfl	ammatory effects of the photobiomodulation

Boolean builder	Mesh terms			
	"Photobiomodulation" or "Low-Level Laser Therapy" or "LLLT"			
And	"Brain"			
And	"Inflammation" or "Cytokines" or "Microglia" or "Neuroinflammation"			

(Hamblin, 2017). The search strategy included experimental *in vivo* animal studies conducting PBM. We accepted only publications written in English. Neither *in vitro* approaches, clinical original articles, conference papers, nor review articles were included.

#### Data extraction and data synthesis

The included articles were divided according to pathological conditions. For data extraction, groups were subdivided according to the references (author and year), characteristics of the population (animals/species, sex and age), PBM parameters: light source/wavelength, continuous wave (CW) or pulsing mode, output power, irradiance per session, irradiation time, fluence per session, energy per session, irradiation approach/site, number of treatment sessions, and studies outcomes.

#### Results

The initial systematic search in PubMed and ScienceDirect databases identified 140 articles. Among them, 54 articles were removed for duplication and 59 articles by screening selection criteria. Then, 27 studies met the inclusion criteria (Figure 1).

## Characteristics of the studies

Twenty seven articles reported experiments in rodents, of which 3 were performed on albino BALB/c mice (Salehpour et al., 2019a,b; Hosseini et al., 2022), 6 used C57BL/6 mice (Khuman et al., 2012; Zhang et al., 2014; Gonçalves et al., 2016; Lee et al., 2016, 2017; Duarte et al., 2018), 1 was conducted on the 5XFAD transgenic mice (pigmented C57BL/6 background) (Cho et al., 2020), 1 was performed on the APP/PS1 transgenic mice (Wu et al., 2021), 2 used the TgF344 transgenic mice (Yang et al., 2021b, 2022), 6 were performed using Wistar rats (Moreira et al., 2009; Prianti et al., 2014; Cardoso et al., 2021a, 2022; Gerace et al., 2021; Vogel et al., 2021), and 8 used Sprague-Dawley rats

(Lu et al., 2017; Esenaliev et al., 2018; Yang et al., 2018, 2021a; O'Brien and Austin, 2019; Di Paolo, 2021; Wang et al., 2021; Tsai et al., 2022). In these laboratory rodent studies, the age of animals varied from 7 weeks old to 20 months old. In order to analyze the anti-inflammatory effects of PBM on brain, we reviewed various animal models such as focal brain damage (Moreira et al., 2009), controlled cortical impact (Khuman et al., 2012), peripheral inflammation (Prianti et al., 2014), mild traumatic brain injury (Zhang et al., 2014), spinal cord injury (Wang et al., 2021), Aβtreatment (Lu et al., 2017), AB and PS1 transgenic rodents (Cho et al., 2020), PS1 transgenic rodents (Wu et al., 2021), TgF344 transgenic rodents (Yang et al., 2021b, 2022), brain ischemia (Lee et al., 2016, 2017; Gerace et al., 2021; Vogel et al., 2021), multiple sclerosis (Gonçalves et al., 2016), natural aging (Cardoso et al., 2021a, 2022), blast injury (Esenaliev et al., 2018), retinal degeneration (Di Paolo, 2021), induced aging (Hosseini et al., 2022), cuprizone-induced demyelination (Duarte et al., 2018), photothrombotic stroke (Yang et al., 2018), lipopolysaccharide-induced Parkinson's disease (O'Brien and Austin, 2019), experimental model of epilepsy (Tsai et al., 2022), restraint stress-induced depression experimental model (Salehpour et al., 2019a), transient global brain ischemia and artificially aging (Salehpour et al., 2019b), and neonatal hypoxic ischemia (Yang et al., 2021a).

The laser parameters used in the studies showed wide divergence:

Light source/ wavelength (nm): LED and LASER, 610 to 905;

Operation mode: CW and pulsed; Output power (W): 0.03 to 1.91; Irradiance (mW/cm<sup>2</sup>): 0.457 to 100; Irradiation time per session (s): 3 to 3,600; Total fluence (J/cm<sup>2</sup>): 1.0 to 535.7;

Energy (J): 0.6 to 294;

**Irradiation approach/sites:** contact to the rat skin immediately over the lesion site, transcranial, in the open craniotomy, in the spinal cord, on the abdomen of pregnant rats, in the cells and percutaneous.

Number of treatment sessions: 1 to 207.

The selected studies were summarized in a chronological order shown in Table 2.

# Findings and discussion

The purpose of this systematic review was to investigate the neuroinflammatory effects of PBM therapy. Studies have shown interesting findings on the anti-inflammatory effects of PBM in various animal models of neurological diseases in different neurological conditions, such as traumatic brain injury, edema formation and hyperalgesia, ischemia, neurodegenerative conditions, aging, and depression.



## Traumatic brain injury

Studies using laboratory animals have shown that PBM reduces the level of pro-inflammatory cytokines and the microglia activation of TBI animal models (Moreira et al., 2009; Khuman et al., 2012; Esenaliev et al., 2018; Yang et al., 2018). For example, Khuman et al. (2012) demonstrated that 800 nm laser PBM inhibited the microglia activation, accompanied by improvement in cognitive deficits after controlled cortical impact. Esenaliev et al. (2018) observed that one session of 808 nm nano-pulsed laser PBM therapy applied 1 h after blast injury significantly inhibited microglia activation and reduced the number of cortical neurons expressing activated caspase-3 in a rat model of blast-induced neurotrauma. Also, in the study conducted by Yang et al. (2018), 9 sessions of 808 nm laser PBM was able to change the phenotype of microglial polarization from the M1 pro-inflammatory phenotype to the M2 anti-inflammatory phenotype. Since TBI is accompanied by an increase in cytokine and chemokine levels (Woodcock and Morganti-Kossmann, 2013; Bergold, 2016), the severity of brain damage is linked to a higher and more prolonged inflammatory response (Kumar and Loane, 2012; White et al., 2013; Woodcock and Morganti-Kossmann, 2013; Lozano et al., 2015). In animals, an increase in cerebral cortical levels of the inflammatory cytokines IL-1β, TNFa, and IL-6 has been shown from 3 to 9h after injury (Bachstetter et al., 2013). In clinical studies, levels of pro-inflammatory markers IL-6, TNFa, IL-10, IL-8, and monocyte chemoattractant protein-1 (MCP-1) have also been increased after 2 days of TBI (Morganti-Kossman et al., 1997; Csuka et al., 1999; Semple et al., 2010). In addition, the release of these cytokines was correlated with

microglial activation and axonal dysfunction, suggesting an association between the activated immune response and brain injury (Frugier et al., 2010). Taken together, it seems that PBM can exert anti-inflammatory action against TBI through the modulation of both anti- and pro-inflammatory chemokines and cytokines.

## Edema formation and hyperalgesia

In the study by Prianti et al. (2014), they showed that 660 nm laser PBM reduces COX-2 mRNA expression in animals receiving carrageenan. This is a worthwhile result as in inflammatory conditions COX-2 is highly expressed, increasing the release of pro-inflammatory markers (Schuligoi et al., 2003; Grill et al., 2006, 2008), and plays a key role in chronic pain (Narita et al., 2008).

## Brain ischemia

Ischemia can trigger an imbalance between pro- and antiinflammatory mediators (Yilmaz and Granger, 2008), which play a key role in the progression and pathogenesis of ischemia (Barone and Feuerstein, 1999; Samson et al., 2005; Chamorro and Hallenbeck, 2006; Wang et al., 2007). For example, the inhibition of inflammatory response in ischemic patients can decrease the brain injury (Yilmaz and Granger, 2008). The therapeutic effects of PBM on ischemia have been addressed in the works by Zhang et al. (2014), Lee et al. (2016, 2017), Salehpour et al. (2019b), Vogel et al. (2021), Yang et al. (2021a) and Gerace et al. (2021). Lee et al. (2016, 2017) treated mice submitted to a focal brain ischemia experimental model with a 610 nm laser and observed an inhibition of Iba-1 and GFAP-labeled cells, accompanied by a regulation of pro-inflammatory cytokines and suppression of mitogen activated protein kinase (MAPK) (a signaling pathway linked to inflammation and cell death) and NF-kB activation. Salehpour et al. (2019b) showed that 14 sessions of 810 nm laser PBM significantly decreased iNOS, TNF- $\alpha$ , and IL-1 $\beta$  levels in the brain of transient global cerebral cortex ischemia model using artificially aged mice. This evidence is promising since activation of MAPKs p38, ERK and JNK regulate pro-inflammatory genes that activate NF-kB in microglia.

#### Neurodegenerative conditions

Abnormal microglial activation and inflammatory response may contribute to the pathology of several neurodegenerative conditions (Chen et al., 2016; Swaroop et al., 2016; Shabab et al., 2017; Voet et al., 2019). It is known that patients with multiple sclerosis (Huang et al., 2020), Alzheimer's disease (Licastro et al., 2000), and Parkinson's disease (Liu et al., 2003) exhibit elevated levels of pro-inflammatory markers in plasma. Transcranial PBM therapy has anti-inflammatory effects in several models of neurodegenerative conditions (Gonçalves et al., 2016; Lu et al., 2017; Duarte et al., 2018; O'Brien and Austin, 2019; Cho et al., 2020; Di Paolo, 2021; Wu et al., 2021; Yang et al., 2021b, 2022). For instance, Gonçalves et al. (2016) submitted mice to a model of multiple sclerosis to 30 sessions of either 660 nm or 904 nm laser PBM therapy. PBM-treated mice exhibited decreased levels of IL-1 $\beta$ , IL-17 and interferon- $\gamma$  (IFN- $\gamma$ ) in the spinal cord, when compared to the control group mice. In addition, Duarte et al. (2018) demonstrated that 6 sessions of 808 nm laser PBM modulate microglial and astrocytes activation induced by cuprizone. In  $A\beta\mbox{-treated}$  mice, PBM treatment also reduced microglia (Iba-1 immunoreactivity) in the cerebral cortex (Cho et al., 2020), and attenuated the elevation of glial activation and IL-1 $\beta$ , IL-6, and TNF- $\alpha$  levels in the hippocampal CA1 region (Lu et al., 2017). Furthermore, O'Brien and Austin (2019) observed that PBM protected against lipopolysaccharideinduced dopaminergic cell death in a rat Parkinson's disease experimental model.

# Aging

Brain aging is characterized by microglia reactivity and an imbalance between pro- and anti-inflammatory cytokines (Godbout and Johnson, 2009; Jurgens and Johnson, 2012). However, a couple of recent studies involving our group have shown that PBM can improve the inflammatory response in the aging brain (Salehpour et al., 2019b; Cardoso et al., 2021a, 2022; Hosseini et al., 2022). For example, a protocol with 58 consecutive days of 810 nm laser PBM therapy was able to change the inflammatory profile of the aging brain in rats. We showed that PBM increased cerebral cortex levels of IL-10, IL-6, and TNF- $\alpha$ . In addition, PBM therapy significantly decreased cerebral cortex levels of IL-5 and hippocampal levels of IP-10 and fractalkine (Cardoso et al., 2021a). In addition, we reported that 10 sessions of 660 nm laser PBM Increased levels of IL-1 $\alpha$  and decreased levels of IL-5 in the cerebral cortex. In the hippocampus, the laser treatment increased the levels of IL-1 $\alpha$  and decreased levels of IL-5, IL-18, and fractalkine (Cardoso et al., 2022). These findings are promising, since the expression of pro-inflammatory cytokines, oxidative stress, and glial activation are increased during the aging (Lee et al., 2000; Blalock et al., 2003; Godbout et al., 2005; Bishop et al., 2010).

# Epilepsy

In the study conducted by Tsai et al. (2022), they showed that 608 nm laser PBM reduced neuron-specific enolase (NSE) and glial fibrillary acid protein (GFAP) immunoreactivity in hippocampus in an animal model of epilepsy. These results are promising since studies suggest inflammation as a biomarker in epilepsy (Ravizza et al., 2008; Auvin et al., 2010; Vezzani and Friedman, 2011; Vezzani et al., 2016). For example, blocking IL-1 $\beta$  (a pro-inflammatory interleukin) prevents generalized seizure and increases the threshold for induction of afterdischarge (Ravizza et al., 2008; Auvin et al., 2010).

#### Depression

Salehpour et al. (2019a) observed that 5 sessions of 810 nm laser PBM suppressed neuroinflammatory responses in the neocortex and hippocampus of mice submitted to a restraint stress-induced depression model by decreasing NF-kB, p38, and JNK levels. In addition, PBM decreased the serum levels of cortisol, corticosterone, TNF- $\alpha$ , and IL-6 induced by restraint stress. These results are promising since evidence suggests that these pro-inflammatory proteins are involved in the pathology of major depressive disorder (Kubera et al., 2011; Liu et al., 2012), as well as neurotransmission and mood regulation (Du et al., 2008; Villanueva, 2013).

#### Spinal cord injury

In the study conducted by Wang et al. (2021) it was observed that microglia and astrocytes begin to be activated after spinal cord injury, participating in secondary damage and tissue repair. However, 810 nm laser PBM during two consecutive weeks was able to inhibit microglia/macrophage and astrocyte activation TABLE 2 Summary of laboratory animal studies on neuroinflammatory effects of the photobiomodulation.

Author	Animal/Species	Model	Laser Parameters	Outcomes
Moreira et al. (2009)	Fifty-one Male Wistar rats	Focal brain damage	Light source/ wavelength (nm): LED, 660 and 780 Operation mode: CW Output power (W): 0.04 Irradiation time per session (s): 3 and 5 Energy (J): 24 and 40 Irradiation approach/sites: contact to the rat skin immediately over the lesion site. Number of treatment sessions: 2	Modulation of TNF- $\alpha$ , IL-1 $\beta$ and IL-6 levels in the brain and in circulation in the first 24 h following cryogenic brain injury.
Khuman et al. (2012)	Two hundred and thirty-nine Male C57BL/6 mice (3 months old)	Controlled cortical impact	Light source/ wavelength (nm): LASER, 800 Output power (W): 0.33, 0.65, 1.3 Irradiance (mW/cm <sup>2</sup> ): 250, 500 and 1,000 Irradiation time per session (s): 120 and 420 Total fluence (J/cm <sup>2</sup> ): 30, 60, 105, 120 and 210 Energy (J): 39, 78, 137, 156 and 273 Irradiation approach/sites: in the open craniotomy and transcranial Number of treatment sessions: 1 and 7	Reduction of microgliosis in open craniotomy mice.
Prianti et al. (2014)	Thirty Male Wistar rats	Peripheral inflammation	Light source/ wavelength (nm): LED, 660 Output power (W): 0.03 Irradiation time per session (s): 232 Total fluence (J/cm <sup>2</sup> ): 7.5 Number of treatment sessions: 1	Reduced expression of COX-2 mRNA.
Zhang et al. (2014)	Male C57BL/6 mice (8 weeks old)	Mild traumatic brain injury	Light source/ wavelength (nm): LED, 810 Operation mode: pulsed Irradiance (mW/cm <sup>2</sup> ): 150 Irradiation time per session (s): 240 Total fluence (J/cm <sup>2</sup> ): 36 Irradiation approach/sites: transcranial	Suppressed proinflammatory cytokine expression like IL-1b and IL-6.
Lee et al. (2016)	Eighteen Male C57BL/6J mice	Focal cerebral ischemia	Light source/ wavelength (nm): LED, 610 Operation mode : CW Irradiance (mW/cm <sup>2</sup> ) : 1.7 Total fluence (J/cm <sup>2</sup> ): 2.0 Irradiation approach/sites: transcranial Number of treatment sessions: 4	Inhibited Iba-1- and GFAP-labeled cells, which was accompanied by a reduction in the expression of inflammatory mediators and inhibition of MAPK activation and NF-kB translocation in the ischemic cortex.
Gonçalves et al. (2016)	Female C57BL/6 mice (6–10 weeks old)	Multiple sclerosis	Light source/ wavelength (nm): LED/ 660 and 904 Operation mode: CW and Pulsed Output power (W): 0.3 and 0.7 Irradiation time per session (s): 120 Total fluence (J/cm <sup>2</sup> ): 3 and 10 Energy (J): 0.6 Irradiation approach/sites: in the spinal cord Number of treatment sessions: 30	Neuroinflammation inhibition/modulation through a reduction of inflammatory cells in the CNS.
Lee et al. (2017)	Male C57BL/6J mice	Focal cerebral ischemia	Light source/ wavelength (nm): LED, 610 Irradiance (mW/cm <sup>2</sup> ): 1.7 Irradiation time per session (s): 1,200 Total fluence (J/cm <sup>2</sup> ): 2 Irradiation approach/sites: transcranial Number of treatment sessions: 6	Attenuation of the NLRP3 inflammasome, in accordance with down- regulation of pro-inflammatory cytokines IL-1β and IL-18 in the ischemic brain. In addition, suppressed TLR-2 levels, MAPK signaling and NF-kB activation in the mice with post-is- chemic.

(Continued)

#### TABLE 2 (Continued)

Author	Animal/Species	Model	Laser Parameters	Outcomes
Lu et al. (2017)	Male Sprague- Dawley	Aβ-treatment	Light source/ wavelength (nm): LED, 808	Attenuation of the elevation of glial
	rats		Operation mode : CW	activation and proinflammatory cytokine
			Irradiance (mW/cm <sup>2</sup> ): 25	levels (IL-1 $\beta$ , IL-6 and TNF- $\alpha$ ,) in the
			Irradiation time per session (s): 120	hippocampal CA1 region.
			Total fluence (J/cm <sup>2</sup> ): 15	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 5	
Esenaliev et al.	Fifty Male	Blast injury	Light source/ wavelength (nm): LASER, 808	Inhibition of microglia activation and
(2018)	Sprague-Dawley rats		Operation mode: Pulsed	reduction of the number of cortical neurons
			Irradiation time per session (s): 300	expressing activated caspase-3.
			Total fluence (J/cm <sup>2</sup> ): 300	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 1	
Duarte et al.	Male C57BL/6 mice (7	Demyelination	Light source/ wavelength (nm): LED, 808	Modulation in microglial and astrocytes
(2018)	weeks old)		Operation mode: CW	activation induced by cuprizone.
			Output power (W): 0.5	
			Irradiance (mW/cm <sup>2</sup> ): 178	
			Irradiation time per session (s): 20	
			Total fluence (J/cm <sup>2</sup> ): 36	
			Energy (J): 1	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 6	
Yang et al.	Male Sprague-Dawley	Photothrombotic	Light source/ wavelength (nm): LASER, 808	Modulation of M1 microglial phenotype to
(2018)	rats	stroke	Operation mode : CW	an anti-inflammatory M2 phenotype.
			Irradiance (mW/cm <sup>2</sup> ): 350	
			Irradiation time per session (s): 120	
			Energy (J): 294	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 7	
O'Brien and	Forty-one Male	Local inflammation	Light source/ wavelength (nm): LED, 675	Protection against a dose of LPS sufficient to
Austin (2019)	Sprague-Dawley rats	and microglial	Operation mode: CW	cause 15% dopaminergic cell death.
		activation	Output power (W): 0.5	
			Irradiance (mW/cm <sup>2</sup> ): 40.84	
			Irradiation time per session (s): 88	
			Total fluence (J/cm <sup>2</sup> ): 3.594	
			Energy (J): 35.94	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 13	
Salehpour	Seventy-five Male	Restraint stress	Light source/ wavelength (nm): LASER, 810	Suppression of neuroinflammatory response
et al. (2019a)	BALB/c		Operation mode: Pulsed	in the cortex and hippocampus by decreased
	mice (8-10-weeks-old)		Output power (W): 0.2	NF-kB, p38, and JNK levels. In addition,
			Irradiance (mW/cm <sup>2</sup> ): 666	decreased the serum levels of cortisol,
			Irradiation time per session (s): 5	corticosterone, $\mathrm{TNF}\text{-}\alpha,$ and IL-6 induced by
			Total fluence (J/cm <sup>2</sup> ): 33.3	restraint stress.
			Energy (J): 1	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 5	

(Continued)

Author	Animal/Species	Model	Laser Parameters	Outcomes
Salehpour et al. (2019b)	Ninety Male BALB/c mice (8–10- weeks old)	Transient global brain ischemia in	Light source/ wavelength (nm): LASER, 810 Operation mode: Pulsed	Reduction of iNOS, TNF- $\alpha$ , and IL-1 $\beta$ brain levels.
		artificially aged	Output power (W): 0.2	
			Irradiance (mW/cm <sup>2</sup> ): 666	
			Total fluence (J/cm <sup>2</sup> ): 33.3	
			Energy (J): 1	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 14	
Cho et al.	5XFAD transgenic male	Aβ and OS1 treated	Light source/ wavelength (nm): LED, 610	Reduced microglia (Iba-1 immunoreactivity)
(2020)	mice (10 months old)		Irradiance (mW/cm <sup>2</sup> ): 1./	in the cerebral cortex.
			Irradiation time per session (s): 1,200	
			Total fluence (J/cm <sup>2</sup> ): 2.0	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 42	
Cardoso et al.	Sixty-four Male Wistar	Aging	Light source/ wavelength (nm): LED, 810	Increased cerebral cortex levels of IL-10, IL-6,
(2021a)	rats (4 and 20 months		Operation mode: CW	and $TNF\alpha$ , and decreased IL-5. Also,
	old)		Output power (W): 0.1	decreased hippocampal levels of IP-10 and
			Irradiance (mW/cm <sup>2</sup> ): 357	fractalkine.
			Irradiation time per session (s): 150	
			Total fluence (J/cm <sup>2</sup> ): 535.7	
			Energy (J): 15	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 58	
Yang et al.	Thirty Male and female	Neonatal hypoxic	Light source/ wavelength (nm): LED, 808	Settled hypoxic-ischemic-induced
(2021a)	Sprague- Dawley rats (11	ischemia	Irradiance (mW/cm <sup>2</sup> ): 350 and 8 on neonatal brain	neuroinflammation, oxidative stress, and
	weeks old)		Irradiation time per session (s): 120	myeloid cell/astrocyte activation.
			Irradiation approach/sites: on the abdomen of	
			pregnant rats	
			Number of treatment sessions: 9	
Wu et al.	Ninety-six APP/PS1	OS1 treatment	Light source/ wavelength (nm): LED, 635	Expression of glial fibrillary acidic protein
(2021)	transgenic mice (6		Output power (W): 0.1	(GFAP) inhibition.
	months old)		Irradiance (mW/cm <sup>2</sup> ): 12.74	
			Irradiation time per session (s): 75, 150 and 300	
			Total fluence (J/cm <sup>2</sup> ): 1, 2 and 4	
			Irradiation approach/sites: in the cells	
			Number of treatment sessions: 1	
Vogel et al.	Fifty Male Wistar rats	Ischemic stroke	Light source/ wavelength (nm): LED, 780	Reduced of TNF- $\alpha$ , IL-1 $\beta$ and IL-6 and
(2021)			Output power (W): 0.150	microglial activation.
			Irradiance (mW/cm <sup>2</sup> ): 10	
			Irradiation time per session (s): 120	
			Total fluence (J/cm <sup>2</sup> ): 10	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 25	
Wang et al.	Two hundred and	Spinal cord injury	Light source/ wavelength (nm): LED, 810	Inhibition of the activation of neurotoxic
(2021)	seventy-nine Male		Operation mode: CW	microglia, neuroinflammation alleviation.
	Sprague- Dawley rats		Output power (W): 1.0	
			Irradiation time per session (s): 3600	
			Irradiation approach/sites: percutaneous	
			Number of treatment sessions: 14	

(Continued)

#### TABLE 2 (Continued)

Author	Animal/Species	Model	Laser Parameters	Outcomes
Yang et al.	Thirty-two Male TgF344	A4 and PS1	Light source/ wavelength (nm): LED, 808	Neuroinflammation and oxidative stress
(2021b)	rats (2 months old)	treatment	Operation mode: CW	decrease.
			Irradiance (mW/cm <sup>2</sup> ): 350	
			Irradiation time per session (s): 120	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 103	
Di Paolo	Male Sprague- Dawley	Retinal Degeneration	Light source/ wavelength (nm): LED, 670	Mitigation of the microglial activation.
(2021)	rats		Irradiation time per session (s): 180	
			Total fluence (J/cm <sup>2</sup> ): 4.5	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 7	
Gerace et al.	Male and female Wistar	Cerebral	Light source/ wavelength (nm): LED, 808 and 905	Attenuation of inflammatory mechanisms.
(2021)	rats (7-9 days old)	Hypoxia/Ischemia	Operation mode: CW and pulsed	
			Output power (W): 1.91	
			Irradiance (mW/cm <sup>2</sup> ): 620	
			Irradiation time per session (s): 6, 12 e 24	
			Total fluence (J/cm <sup>2</sup> ): 3.71, 7.42 and 14.84	
			Irradiation approach/sites: in the cells	
			Number of treatment sessions: 1	
Hosseini et al.	Fifty Male BALB/c mice	Aging	Light source/ wavelength (nm): LED, 810	Decrease of TNF- $\alpha$ and IL-6;
(2022)			Output power (W): 0.2	down-regulation of GAP-43 and SYN
			Irradiance (mW/cm <sup>2</sup> ): 0.457	inhibition.
			Irradiation time per session (s): 5, 10 and 20	
			Total fluence (J/cm <sup>2</sup> ): 8, 16 and 32	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 24	
Cardoso et al.	Ten Male Wistar rats (20	Aging	Light source/ wavelength (nm): LED, 660	Increased levels of IL-1 $\alpha$ and decreased levels
(2022)	months old)		Operation mode: CW	of IL-5 in the cerebral cortex. In the
			Output power (W): 0.1	hippocampus, the laser treatment increased
			Irradiance (mW/cm <sup>2</sup> ): 357	the levels of IL-1 $\alpha$ and decreased levels of
			Irradiation time per session (s): 150	IL-5, IL-18, and fractalkine.
			Total fluence (J/cm <sup>2</sup> ): 535.7	
			Energy (J): 15	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 10	
Tsai et al.	Male Sprague- Dawley	Epilepsy	Light source/ wavelength (nm): LED, 808	Reduced NSE immunoreactivity in CA3,
(2022)	rats	* * *	Operation mode: CW	GFAP immunoreactivity in CA1, and Iba-1
			Output power (W): 0.11	immunoreactivity in CA3.
			Irradiance (mW/cm <sup>2</sup> ): 133.3	
			Irradiation time per session (s): 100	
			Total fluence (I/cm <sup>2</sup> ): 133 3	
			Energy (I): 11	
			Irradiation approach/sites: transcranial	
			Number of treatment sessions: 1	
Yang et al	Sixty-four Male ToF344	A4 and PS1	Light source/ wavelength (nm): LED 808	Regulation of glial cell polarization and
(2022)	rate (2 months old)	treatment	Operation mode: CW	inhibition of neuroinflammation
(2022)	1410 (2 11011110 010)	acatinellt	Irradiance (mW/cm <sup>2</sup> ). 350	annotion of neuronmanifiation.
			Irradiation time nor specian (c), 120	
			Total fluence (I/cm <sup>2</sup> ): 42	
			Ivra diation approach (sites: transmist)	
			Number of treatment and 207	
			number of treatment sessions: 207	

after spinal cord injury. In this regard, PBM may be a useful tool for the treatment of spinal cord injury, in association to antibody-based approaches to interrupt endothelial-monocyte interactions, reducing macrophage activation at the injured spinal cord and also to pharmacological therapies focusing on immunomodulation and promotion of reparative glia activity (Orr and Gensel, 2018).

#### Limitations

Our review presents limitations. The researches highlighted in this review describe several brain conditions and methodologies, and the lack of some details about the PBM parameters used in each work make it difficult to replicate these approaches. Standardization of the protocols for each condition would facilitate comparison between the findings of the studies and could improve the translational application of PBM therapy.

# Conclusion

Neuroinflammation is a pathological condition in a variety of brain insults and neurodegenerative conditions. Despite using very different protocols, the reviewed studies showed that the therapeutic effects of transcranial PBM therapy in animal models of neurological and psychiatric diseases are related to the capacity to reduce levels of pro-inflammatory mediators and increase levels of anti-inflammatory mediators. In addition, no adverse effects of PBM on the brain were found. Therefore, PBM could safely fit in to complement current treatments for the conditions listed above. These results mean that for the current use of PBM, controlled human studies are needed as a nextstep of research to build on these animal studies. Despite not excluding human studies as a keyword, no controlled human studies were discovered in the present review, and all the included studies were animal studies. Human studies could bring new perspectives on the anti-inflammatory property of PBM in brain disorders. The reviewed animal studies together with consistent human studies of PBM in the treatment of neuroinflammation can suggest that transcranial PBM is a promising strategy for the treatment of neuroinflammationinduced brain diseases.

# References

Almeida, P., Lopes-Martins, R. Á., Tomazoni, S. S., Albuquerque-Pontes, G. M., Santos, L. A., Vanin, A. A., et al. (2013). Low-level laser therapy and sodium diclofenac in acute inflammatory response induced by skeletal muscle trauma: effects in muscle morphology and mRNA gene expression of inflammatory markers. *Photochem. Photobiol.* 89, 501–507. doi: 10.1111/j.1751-1097.2012. 01232.x

# Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

# Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

# Funding

This study was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (grants 2017/16443-0, 2021/06473-4, and 2020/15050-7). FG-L was supported by the Oskar Fischer Project Fund.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fnins.2022.1006031/full#supplementary-material

Anders, J. J., Lanzafame, R. J., and Arany, P. R. (2015). Low-level light/laser therapy versus photobiomodulation therapy. *Photomed. Laser Surg.* 33, 183–184. doi: 10.1089/pho.2015.9848

Arany, P. R. (2016). Craniofacial wound healing with photobiomodulation therapy: new insights and current challenges. J. Dent. Res. 95, 977–984. doi: 10.1177/0022034516648939

Auvin, S., Shin, D., Mazarati, A., and Sankar, R. (2010). Inflammation induced by LPS enhances epileptogenesis in immature rat and may be partially reversed by IL1RA. *Epilepsia* 51, 34–38. doi: 10.1111/j.1528-1167.2010.02606.x

Bachstetter, A. D., Rowe, R. K., Kaneko, M., Goulding, D., Lifshitz, J., and Van Eldik, L. J. (2013). The p38α MAPK regulates microglial responsiveness to diffuse traumatic brain injury. *J. Neurosci.* 33, 6143–6153. doi: 10.1523/JNEUROSCI.5399-12.2013

Barone, F. C. and Feuerstein, G. Z. (1999). Inflammatory mediators and stroke: new opportunities for novel therapeutics. *J. Cereb. Blood Flow Metab.* 19, 819–834. doi: 10.1097/00004647-199908000-00001

Bergold, P. J. (2016). Treatment of traumatic brain injury with anti-inflammatory drugs. *Exp. Neurol.* 275, 367–380. doi: 10.1016/j.expneurol.2015.05.024

Bishop, N. A., Lu, T., and Yankner, B. A. (2010). Neural mechanisms of ageing and cognitive decline. *Nature* 464, 529–535. doi: 10.1038/nature08983

Blalock, E. M., Chen, K. C., Sharrow, K., Herman, J. P., Porter, N. M., Foster, T. C., et al. (2003). Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. *J. Neurosci.* 23, 3807–3819. doi: 10.1523/JNEUROSCI.23-09-03807.2003

Cardoso, F., Tavares, C. D. S. O., Araujo, B. H. S., Mansur, F., Lopes-Martins, R. A. B., and Gomes da Silva, S. (2021a). Improved spatial memory and neuroinflammatory profile changes in aged rats submitted to photobiomodulation therapy. *Cell. Mol. Neurobiol.* 42, 1875–1886. doi: 10.1007/s10571-021-01069-4

Cardoso, F. D. S., dos Santos, J. C. C., Gonzalez-Lima, F., Araújo, B. H. S., Lopes-Martins, R. Á. B., and Gomes da Silva, S. (2021c). Effects of chronic photobiomodulation with transcranial near-infrared laser on brain metabolomics of young and aged rats. *Mol. Neurobiol.* 58, 2256–2268. doi: 10.1007/s12035-020-02247-z

Cardoso, F. D. S., Gonzalez-Lima, F., and Gomes da Silva, S. (2021b). Photobiomodulation for the aging brain. *Ageing Res. Rev.* 70, 101415. doi: 10.1016/j.arr.2021.101415

Cardoso, F. D. S., Mansur, F. C. B., Araújo, B. H. S., Gonzalez-Lima, F., and Gomes da Silva, S. (2022). Photobiomodulation improves the inflammatory response and intracellular signaling proteins linked to vascular function and cell survival in the brain of aged rats. *Mol. Neurobiol.* 59, 420–428. doi: 10.1007/s12035-021-02606-4

Cardoso, F. D. S., Mansur, F. C. B., Lopes-Martins, R. À. B., Gonzalez-Lima, F., and Gomes da Silva, S. (2021d). Transcranial laser photobiomodulation improves intracellular signaling linked to cell survival, memory and glucose metabolism in the aged brain: a preliminary study. *Front. Cell. Neurosci.* 15, 683127. doi: 10.3389/fncel.2021. 683127

Carson, M. J., Thrash, J. C., and Walter, B. (2006). The cellular response in neuroinflammation: the role of leukocytes, microglia and astrocytes in neuronal death and survival. *Clin. Neurosci. Res.* 6, 237–245. doi: 10.1016/j.cnr.2006. 09.004

Chamorro, Á., and Hallenbeck, J. (2006). The harms and benefits of inflammatory and immune responses in vascular disease. *Stroke*. 37, 291–293. doi: 10.1161/01.STR.0000200561.69611.f8

Chen, W. W., Zhang, X. I. A., and Huang, W. J. (2016). Role of neuroinflammation in neurodegenerative diseases. *Mol. Med. Rep.* 13, 3391–3396. doi: 10.3892/mmr.2016.4948

Cho, G. M., Lee, S. Y., Park, J. H., Kim, M. J., Park, K. J., Choi, B. T., et al. (2020). Photobiomodulation using a low-level light-emitting diode improves cognitive dysfunction in the 5XFAD mouse model of Alzheimer's disease. *J. Gerontol. A Biol. Sci. Med. Sci.* 75, 631–639. doi: 10.1093/gerona/gly240

Csuka, E., Morganti-Kossmann, M. C., Lenzlinger, P. M., Joller, H., Trentz, O., and Kossmann, T. (1999). IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF- $\alpha$ , TGF- $\beta$ 1 and blood-brain barrier function. J. Neuroimmunol. 101, 211–221. doi: 10.1016/S0165-5728(99)00148-4

Cunningham, A. J., Murray, C. A., O'neill, L. A. J., Lynch, M. A., and O'connor, J. J. (1996). Interleukin-1 $\beta$  (IL-1 $\beta$ ) and tumour necrosis factor (TNF) inhibit long-term potentiation in the rat dentate gyrus in vitro. *Neurosci. Lett.* 203, 17–20. doi: 10.1016/0304-3940(95)12252-4

De Vries, H. E., Blom-Roosemalen, M. C., van Oosten, M., De Boer, A. G., Van Berkel, T. J., Breimer, D. D., et al. (1996). The influence of cytokines on the integrity of the blood-brain barrier in vitro. *J. Neuroimmunol.* 64, 37–43. doi:10.1016/0165-5728(95)00148-4

Di Paolo, M. (2021). Sequential PBM-saffron treatment in an animal model of retinal degeneration. *Medicina* 57, 1059. doi: 10.3390/medicina57101059

DiSabato, D. J., Quan, N., and Godbout, J. P. (2016). Neuroinflammation: the devil is in the details. *J. Neurochem.* 139, 136–153. doi: 10.1111/jnc.13607

Du, J., Creson, T. K., Wu, L. J., Ren, M., Gray, N. A., Falke, C., et al. (2008). The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. *J. Neurosci.* 28, 68–79. doi: 10.1523/JNEUROSCI.3080-07.2008

Duarte, K. C. N., Soares, T. T., Magri, A. M. P., Garcia, L. A., Le Sueur-Maluf, L., Renno, A. C. M., et al. (2018). Low-level laser therapy modulates demyelination in mice. *J. Photochem. Photobiol. B.* 189, 55–65. doi: 10.1016/j.jphotobiol.2018.09.024

Esenaliev, R. O., Petrov, I. Y., Petrov, Y., Guptarak, J., Boone, D. R., Mocciaro, E., et al. (2018). Nano-pulsed laser therapy is neuroprotective in a rat model of blast-induced neurotrauma. *J. Neurotrauma* 35, 1510–1522. doi: 10.1089/neu.2017.5249

Frugier, T., Morganti-Kossmann, M. C., O'Reilly, D., and McLean, C. A. (2010). In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury. *J. Neurotrauma* 27, 497–507. doi 10.1089/neu.2009.1120

Gerace, E., Cialdai, F., Sereni, E., Lana, D., Nosi, D., Giovannini, M. G., et al. (2021). NIR Laser photobiomodulation induces neuroprotection in an in vitro model of cerebral hypoxia/ischemia. *Mol. Neurobiol.* 58, 5383–5395. doi:10.1007/s12035-021-02496-6

Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., and Gage, F. H. (2010). Mechanisms underlying inflammation in neurodegeneration. *Cell*, 140, 918–934. doi 10.1016/j.cell.2010.02.016

Godbout, J. P., Chen, J., Abraham, J., Richwine, A. F., Berg, B. M., Kelley, K. W., et al. (2005). Exaggerated neuroinflammation and sickness behavior in aged mice after activation of the peripheral innate immune system. *FASEB J.* 19, 1329–1331. doi: 10.1096/fj.05-3776fje

Godbout, J. P. and Johnson, R. W. (2009). Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. *Immunol. Allergy Clin. North Am.* 29, 321–337. doi: 10.1016/j.iac.2009.02.007

Gonçalves, E. D., Souza, P. S., Lieberknecht, V., Fidelis, G. S., Barbosa, R. I., Silveira, P. C., et al. (2016). Low-level laser therapy ameliorates disease progression in a mouse model of multiple sclerosis. *Autoimmunity*. 49, 132–142. doi: 10.3109/08916934.2015.1124425

Grazioli, S. and Pugin, J. (2018). Mitochondrial damage-associated molecular patterns: from inflammatory signaling to human diseases. *Front. Immunol.* 9, 832. doi: 10.3389/fimmu.2018.00832

Grill, M., Heinemann, A., Hoefler, G., Peskar, B. A., and Schuligoi, R. (2008). Effect of endotoxin treatment on the expression and localization of spinal cyclooxygenase, prostaglandin synthases, and PGD2 receptors. *J. Neurochem.* 104, 1345–1357. doi: 10.1111/j.1471-4159.2007.05078.x

Grill, M., Peskar, B. A., Schuligoi, R., and Amann, R. (2006). Systemic inflammation induces COX-2 mediated prostaglandin D2 biosynthesis in mice spinal cord. *Neuropharmacology*. 50, 165–173. doi: 10.1016/j.neuropharm.2005.08.005

Gupta, A., Keshri, G. K., Yadav, A., Gola, S., Chauhan, S., Salhan, A. K., et al. (2015). Superpulsed (Ga-As, 904 nm) low-level laser therapy (LLLT) attenuates inflammatory response and enhances healing of burn wounds. *J. Biophotonics*. 8, 489–501. doi: 10.1002/jbio.201400058

Hamblin, M. R. (2017). Mechanisms and applications of the antiinflammatory effects of photobiomodulation. *AIMS Biophys.* 4, 337–361. doi: 10.3934/biophy.2017.3.337

Harry, G. J. and Kraft, A. D. (2012). Microglia in the developing brain: a potential target with lifetime effects. *Neurotoxicology* 33, 191-206. doi: 10.1016/j.neuro.2012.01.012

Holmes, E., Barrett, D. W., Saucedo, C. L., O'Connor, P., Liu, H., and Gonzalez-Lima, F. (2019). Cognitive enhancement by transcranial photobiomodulation is associated with cerebrovascular oxygenation of the prefrontal cortex. *Front. Neurosci.* 13, 1129. doi: 10.3389/fnins.2019.01129

Hosseini, L., Farazi, N., Erfani, M., Mahmoudi, J., Akbari, M., Hosseini, S. H., et al. (2022). Effect of transcranial near-infrared photobiomodulation on cognitive outcomes in D-galactose/AlCl3 induced brain aging in BALB/c mice. *Lasers Med. Sci.* 37, 1787–1798. doi: 10.1007/s10103-021-03433-8

Huang, J., Khademi, M., Fugger, L., Lindhe, Ö., Novakova, L., Axelsson, M., et al. (2020). Inflammation-related plasma and CSF biomarkers for multiple sclerosis. *Proc. Natl. Acad. Sci.* 117, 12952–12960. doi: 10.1073/pnas.1912839117

Huang, Y. Y., Chen, A. C. H., Carroll, J. D., and Hamblin, M. R. (2009). Biphasic dose response in low level light therapy. *Dose-response* 7, 09–027. doi: 10.2203/dose-response.09-027.Hamblin

Jurgens, H. A. and Johnson, R. W. (2012). Dysregulated neuronal-microglial cross-talk during aging, stress and inflammation. *Exp. Neurol.* 233, 40–48. doi: 10.1016/j.expneurol.2010.11.014

Karu, T. (1999). Primary and secondary mechanisms of action of visible to near-IR radiation on cells. *J. Photochem. Photobiol. B. Biol.* 49, 1–17. doi: 10.1016/S1011-1344(98)00219-X

Karu, T., Pyatibrat, L., and Kalendo, G. (1995). Irradiation with He-Ne laser increases ATP level in cells cultivated in vitro. *J. Photochem. Photobiol. B. Biol.* 27, 219–223. doi: 10.1016/1011-1344(94)07078-3

Karu, T. I., Pyatibrat, L. V., and Afanasyeva, N. I. (2005). Cellular effects of low power laser therapy can be mediated by nitric oxide. *Lasers Surg. Med.* 36, 307–314. doi: 10.1002/lsm.20148

Khuman, J., Zhang, J., Park, J., Carroll, J. D., Donahue, C., and Whalen, M. J. (2012). Low-level laser light therapy improves cognitive deficits and inhibits microglial activation after controlled cortical impact in mice. *J. Neurotrauma.* 29, 408–417. doi: 10.1089/neu.2010.1745

Kubera, M., Obuchowicz, E., Goehler, L., Brzeszcz, J., and Maes, M. (2011). In animal models, psychosocial stress-induced (neuro) inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. *Progr. Neuropsychopharmacol. Biol. Psychiatry.* 35, 744–759. doi: 10.1016/j.pnpbp.2010.08.026

Kumar, A. and Loane, D. J. (2012). Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. *Brain Behav. Immun.* 26, 1191–1201. doi: 10.1016/j.bbi.2012.06.008

Laflamme, N., Lacroix, S., and Rivest, S. (1999). An essential role of interleukin-1 $\beta$  in mediating NF- $\kappa$ B activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. *J. Neurosci.* 19, 10923–10930. doi:10.1523/JNEUROSCI.19-24-10923.1999

Lee, C. K., Weindruch, R., and Prolla, T. A. (2000). Gene-expression profile of the ageing brain in mice. *Nat. Genet.* 25, 294–297. doi: 10.1038/77046

Lee, H. I., Lee, S. W., Kim, N. G., Park, K. J., Choi, B. T., Shin, Y. I., et al. (2017). Low-level light emitting diode (LED) therapy suppresses inflammasome-mediated brain damage in experimental ischemic stroke. *J. Biophotonics*. 10, 1502–1513. doi: 10.1002/jbio.201600244

Lee, H. I., Park, J. H., Park, M. Y., Kim, N. G., Park, K. J., Choi, B. T., et al. (2016). Pre-conditioning with transcranial low-level light therapy reduces neuroinflammation and protects blood-brain barrier after focal cerebral ischemia in mice. *Restor. Neurosci.* 34, 201–214. doi: 10.3233/RNN-150559

Licastro, F., Pedrini, S., Caputo, L., Annoni, G., Davis, L. J., Ferri, C., et al. (2000). Increased plasma levels of interleukin-1, interleukin-6 and  $\alpha$ -1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? *J. Neuroimmunol.* 103, 97–102. doi: 10.1016/S0165-5728(99)00226-X

Liu, B., Gao, H. M., and Hong, J. S. (2003). Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. *Environ. Health Perspect.* 111, 1065–1073. doi: 10.1289/ehp.6361

Liu, Y., Ho, R. C. M., and Mak, A. (2012). Interleukin (IL)-6, tumour necrosis factor alpha (TNF- $\alpha$ ) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. *J. Affect. Disord.* 139, 230–239. doi: 10.1016/j.jad.2011.08.003

Lozano, D., Gonzales-Portillo, G. S., Acosta, S., de la Pena, I., Tajiri, N., Kaneko, Y., et al. (2015). Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. *Neuropsychiatr. Dis. Treat.* 11, 97–106. doi: 10.2147/NDT.S65815

Lu, Y., Wang, R., Dong, Y., Tucker, D., Zhao, N., Ahmed, M. E., et al. (2017). Low-level laser therapy for beta amyloid toxicity in rat hippocampus. *Neurobiol. Aging* 49, 165–182. doi: 10.1016/j.neurobiolaging.2016.10.003

Lyman, M., Lloyd, D. G., Ji, X., Vizcaychipi, M. P., and Ma, D. (2014). Neuroinflammation: the role and consequences. *Neurosci. Res.* 79, 1–12. doi: 10.1016/j.neures.2013.10.004

Martins, D. F., Turnes, B. L., Cidral-Filho, F. J., Bobinski, F., Rosas, R. F., Danielski, L. G., et al. (2016). Light-emitting diode therapy reduces persistent inflammatory pain: Role of interleukin 10 and antioxidant enzymes. *Neuroscience* 324, 485–495. doi: 10.1016/j.neuroscience.2016.03.035

Moher, D., Liberati, A., Tetzlaff, J., and Altman, D. G. (2010). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int. J. Surg.* 8, 336–341. doi: 10.1016/j.ijsu.2010.02.007

Moreira, M. S., Velasco, I. T., Ferreira, L. S., Ariga, S. K. K., Barbeiro, D. F., Meneguzzo, D. T., et al. (2009). Effect of phototherapy with low intensity laser on local and systemic immunomodulation following focal brain damage in rat. *J. Photochem. Photobiol.* 97, 145–151. doi: 10.1016/j.jphotobiol.2009.09.002

Morganti-Kossman, M. C., Lenzlinger, P. M., Hans, V., Stahel, P., Csuka, E., Ammann, E., et al. (1997). Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. *Mol. Psychiatry* 2, 133–136. doi: 10.1038/sj.mp.4000227

Muili, K. A., Gopalakrishnan, S., Meyer, S. L., Eells, J. T., and Lyons, J. A. (2012). Amelioration of experimental autoimmune encephalomyelitis in C57BL/6

mice by photobiomodulation induced by  $670\,\mathrm{nm}$  light. PLoS ONE 7, e30655. doi: 10.1371/journal.pone.0030655

Narita, M., Shimamura, M., Imai, S., Kubota, C., Yajima, Y., Takagi, T., et al. (2008). Role of interleukin-1 $\beta$  and tumor necrosis factor- $\alpha$ -dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice. *Neuroscience* 152, 477–486. doi: 10.1016/j.neuroscience.2007.10.039

Norden, D. M., Trojanowski, P. J., Villanueva, E., Navarro, E., and Godbout, J. P. (2016). Sequential activation of microglia and astrocyte cytokine expression precedes increased iba-1 or GFAP immunoreactivity following systemic immune challenge. *Glia* 64, 300–316. doi: 10.1002/glia.22930

O'Brien, J. A. and Austin, P. J. (2019). Effect of photobiomodulation in rescuing lipopolysaccharide-induced dopaminergic cell loss in the male Sprague–Dawley rat. *Biomolecules* 9, 381. doi: 10.3390/biom9080381

Orr, M. B. and Gensel, J. C. (2018). Spinal cord injury scarring and inflammation: therapies targeting glial and inflammatory responses. *Neurotherapeutics* 15, 541–553. doi 10.1007/s13311-018-0631-6

Park, S. E., Sapkota, K., Kim, S., Kim, H., and Kim, S. J. (2011). Kaempferol acts through mitogen-activated protein kinases and protein kinase B/AKT to elicit protection in a model of neuroinflammation in BV2 microglial cells. *Br. J. Pharmacol.* 164, 1008–1025. doi: 10.1111/j.1476-5381.2011.01389.x

Pastore, D., Greco, M., Petragallo, V. A., and Passarella, S. (1994). Increase in H+/e-ratio of the cytochrome c oxidase reaction in mitochondria irradiated with helium-neon laser. *Biochem. Mol. Biol. Int.* 34, 817–826.

Plass, C. A., Loew, H. G., Podesser, B. K., and Prusa, A. M. (2012). Light-induced vasodilation of coronary arteries and its possible clinical implication. *Ann. Thorac. Surg.* 93, 1181–1186. doi: 10.1016/j.athoracsur.2011.12.062

Prianti, A. C. G., Silva, J. A., Dos Santos, R. F., Rosseti, I. B., and Costa, M. S. (2014). Low-level laser therapy (LLLT) reduces the COX-2 mRNA expression in both subplantar and total brain tissues in the model of peripheral inflammation induced by administration of carrageenan. *Lasers Med. Sci.* 29, 1397–1403. doi: 10.1007/s10103-014-1543-2

Ravizza, T., Noé, F., Zardoni, D., Vaghi, V., Sifringer, M., and Vezzani, A. (2008). Interleukin converting enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1 $\beta$  production. *Neurobiol. Dis.* 31, 327–333. doi: 10.1016/j.nbd.2008.05.007

Rojas, J. C. and Gonzalez-Lima, F. (2011). Low-level light therapy of the eye and brain. *Eye Brain* 3, 49–67. doi: 10.2147/EB.S21391

Rojas, J. C. and Gonzalez-Lima, F. (2013). Neurological and psychological applications of transcranial lasers and LEDs. *Biochem. Pharmacol.* 86, 447–457. doi: 10.1016/j.bcp.2013.06.012

Salehpour, F., Farajdokht, F., Cassano, P., Sadigh-Eteghad, S., Erfani, M., Hamblin, M. R., et al. (2019a). Near-infrared photobiomodulation combined with coenzyme Q10 for depression in a mouse model of restraint stress: reduction in oxidative stress, neuroinflammation, and apoptosis. *Brain Res. Bull.* 144, 213–222. doi: 10.1016/j.brainresbull.2018.10.010

Salehpour, F., Farajdokht, F., Mahmoudi, J., Erfani, M., Farhoudi, M., Karimi, P., et al. (2019b). Photobiomodulation and coenzyme Q10 treatments attenuate cognitive impairment associated with model of transient global brain ischemia in artificially aged mice. *Front. Cell. Neurosci.* 13, 74. doi: 10.3389/fncel.2019.00074

Samson, Y., Lapergue, B., and Hosseini, H. (2005). Inflammation and ischaemic stroke: current status and future perspectives. *Rev Neurol*. 161(12 Pt 1), 1177–1182. doi: 10.1016/S0035-3787(05)85190-2

Saucedo, C. L., Courtois, E. C., Wade, Z. S., Kelley, M. N., Kheradbin, N., Barrett, D. W., et al. (2021). Transcranial laser stimulation: mitochondrial and cerebrovascular effects in younger and older healthy adults. *Brain Stimul.* 14, 440–449. doi: 10.1016/j.brs.2021.02.011

Schain, M. and Kreisl, W. C. (2017). Neuroinflammation in neurodegenerative disorders—a review. *Curr. Neurol. Neurosci. Rep.* 17, 25. doi: 10.1007/s11910-017-0733-2

Schuligoi, R., Ulcar, R., Peskar, B. A., and Amann, R. (2003). Effect of endotoxin treatment on the expression on cyclooxygenase-2 and prostaglandin synthases in spinal cord, dorsal root ganglia, and skin of rats. *Neuroscience* 116, 1043–1052. doi: 10.1016/S0306-4522(02)00783-2

Semple, B. D., Bye, N., Rancan, M., Ziebell, J. M., and Morganti-Kossmann, M. C. (2010). Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2–/– mice. *J. Cereb. Blood Flow Metab.* 30, 769–782. doi: 10.1038/jcbfm.2009.262

Shabab, T., Khanabdali, R., Moghadamtousi, S. Z., Kadir, H. A., and Mohan, G. (2017). Neuroinflammation pathways: a general review. *Int. J. Neurosci.* 127, 624–633. doi: 10.1080/00207454.2016.1212854

Swaroop, S., Sengupta, N., Suryawanshi, A. R., Adlakha, Y. K., and Basu, A. (2016). HSP60 plays a regulatory role in IL-1 $\beta$ -induced microglial inflammation via TLR4-p38 MAPK axis. *J. Neuroinflammation* 13, 1–19. doi: 10.1186/s12974-016-0486-x

Tian, F., Hase, S. N., Gonzalez-Lima, F., and Liu, H. (2016). Transcranial laser stimulation improves human cerebral oxygenation. *Lasers Surg. Med.* 48, 343–349. doi: 10.1002/lsm.22471

Tsai, C. M., Chang, S. F., Li, C. C., and Chang, H. (2022). Transcranial photobiomodulation (808 nm) attenuates pentylenetetrazole-induced seizures by suppressing hippocampal neuroinflammation, astrogliosis, and microgliosis in peripubertal rats. *Neurophotonics* 9, 015006. doi: 10.1117/1.NPh.9.1.015006

Vezzani, A. and Friedman, A. (2011). Brain inflammation as a biomarker in epilepsy. *Biomark. Med.* 5, 607–614. doi: 10.2217/bmm.11.61

Vezzani, A., Lang, B., and Aronica, E. (2016). Immunity and inflammation in epilepsy. *Cold Spring Harb. Perspect. Med.* 6, a022699. doi: 10.1101/cshperspect.a022699

Villanueva, R. (2013). Neurobiology of major depressive disorder. *Neural Plast.* 2013, 873278. doi: 10.1155/2013/873278

Voet, S., Prinz, M., and van Loo, G. (2019). Microglia in central nervous system inflammation and multiple sclerosis pathology. *Trends Mol. Med.* 25, 112–123. doi: 10.1016/j.molmed.2018.11.005

Vogel, D. D., Ortiz-Villatoro, N. N., Araújo, N. S., Marques, M. J. G., Aimbire, F., Scorza, F. A., et al. (2021). Transcranial low-level laser therapy in an in vivo model of stroke: Relevance to the brain infarct, microglia activation and neuroinflammation. *J. Biophotonics* 14, e202000500. doi: 10.1002/jbio.202000500

Wang, Q., Tang, X. N., and Yenari, M. A. (2007). The inflammatory response in stroke. J. Neuroimmunol. 184, 53-68. doi: 10.1016/j.jneuroim.2006.11.014

Wang, X., Li, X., Zuo, X., Liang, Z., Ding, T., Li, K., et al. (2021). Photobiomodulation inhibits the activation of neurotoxic microglia and astrocytes by inhibiting Lcn2/JAK2-STAT3 crosstalk after spinal cord injury in male rats. *J. Neuroinflammation* 18, 1–20. doi: 10.1186/s12974-021-02312-x

Wang, X., Reddy, D. D., Nalawade, S. S., Pal, S., Gonzalez-Lima, F., and Liu, H. (2017b). Impact of heat on metabolic and hemodynamic changes in transcranial infrared laser stimulation measured by broadband near-infrared spectroscopy. *Neurophotonics* 5, 011004. doi: 10.1117/1.NPh.5.1.011004

Wang, X., Tian, F., Reddy, D. D., Nalawade, S. S., Barrett, D. W., Gonzalez-Lima, F., et al. (2017a). Up-regulation of cerebral cytochrome-c-oxidase and hemodynamics by transcranial infrared laser stimulation: a broadband nearinfrared spectroscopy study. *J. Cereb. Blood Flow Metab.* 37, 3789–3802. doi: 10.1177/0271678X17691783

White, T. E., Ford, G. D., Surles-Zeigler, M. C., Gates, A. S., LaPlaca, M. C., and Ford, B. D. (2013). Gene expression patterns following unilateral traumatic brain injury reveals a local pro-inflammatory and remote antiinflammatory response. *BMC Genomics* 14, 1–21. doi: 10.1186/1471-2164-14-282

Woodcock, T. and Morganti-Kossmann, C. (2013). The role of markers of inflammation in traumatic brain injury. *Front. Neurol.* 4, 18. doi: 10.3389/fneur.2013.00018

Wu, X., Shen, Q., Zhang, Z., Zhang, D., Gu, Y., and Xing, D. (2021). Photoactivation of TGF $\beta$ /SMAD signaling pathway ameliorates adult hippocampal neurogenesis in Alzheimer's disease model. *Stem Cell Res. Ther.* 12, 1–19. doi: 10.1186/s13287-021-02399-2

Yang, L., Dong, Y., Wu, C., Youngblood, H., Li, Y., Zong, X., et al. (2021a). Effects of prenatal photobiomodulation treatment on neonatal hypoxic ischemia in rat offspring. *Theranostics* 11, 1269. doi: 10.7150/thno.49672

Yang, L., Tucker, D., Dong, Y., Wu, C., Lu, Y., Li, Y., et al. (2018). Photobiomodulation therapy promotes neurogenesis by improving post-stroke local microenvironment and stimulating neuroprogenitor cells. *Exp. Neurol.* 299, 86–96. doi: 10.1016/j.expneurol.2017.10.013

Yang, L., Wu, C., Parker, E., Li, Y., Dong, Y., Tucker, L., et al. (2022). Noninvasive photobiomodulation treatment in an Alzheimer Disease-like transgenic rat model. *Theranostics* 12, 2205. doi: 10.7150/thno.70756

Yang, L., Wu, C., Tucker, L., Dong, Y., Li, Y., Xu, P., et al. (2021b). Photobiomodulation therapy attenuates anxious-depressive-like behavior in the TgF344 rat model. *J Alzheimer's Dis.* 83, 1415–1429. doi: 10.3233/JAD-201616

Yilmaz, G. and Granger, D. N. (2008). Cell adhesion molecules and ischemic stroke. *Neurol. Res.* 30, 783–793. doi: 10.1179/174313208X341085

Yoshimura, T. M., Sabino, C. P., and Ribeiro, M. S. (2016). Photobiomodulation reduces abdominal adipose tissue inflammatory infiltrate of diet-induced obese and hyperglycemic mice. *J. Biophotonics* 9, 1255–1262. doi: 10.1002/jbio.201600088

Zhang, Q., Zhou, C., Hamblin, M. R., and Wu, M. X. (2014). Low-level laser therapy effectively prevents secondary brain injury induced by immediate early responsive gene X-1 deficiency. *J. Cereb. Blood Flow Metab.* 34, 1391–1401. doi: 10.1038/jcbfm.2014.95